Citi Downgrades Allergen (AGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Nasdaq lags on angst over AI spending ahead of earnings reports
Wells Fargo Downgrades Allergen (AGN) to Market Perform
June 25, 2013 6:48 AM EDTWells Fargo downgraded Allergen (NYSE: AGN) from Outperform to Market Perform following generic Restasis documents from the FDA.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $81.99 yesterday, with a 52 week range of $81.28-$116.45.... More
SunTrust Robinson Humphrey Downgrades Allergen (AGN) to Neutral
June 24, 2013 8:10 AM EDTSunTrust Robinson Humphrey downgraded Allergen (NYSE: AGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $92.70 yesterday, with a 52 week range of $81.28-$116.45.... More
Deutsche Bank Downgrades Allergen (AGN) to Hold; Sees 'Overhang' from Generic Restasis
June 24, 2013 7:10 AM EDTDeutsche Bank downgraded Allergen (NYSE: AGN) from Buy to Hold with a price target of $98.00 (from $113.00) after the FDA issued draft guidance for a non-clinical study pathway for generics to Restasis, the company's 2nd largest drug (~14% of revs) with 2015E sales of $1B+.
... More
Leerink Swann Downgrades Allergen (AGN) to Market Perform on Prospect of Restasis Generics
June 24, 2013 7:07 AM EDTLeerink Swann downgraded Allergen (NYSE: AGN) from Outperform to Market Perform with a price target of $102.00 (from $113-$114).
"We are downgrading AGN from Outperform to Market Perform following the release of surprisingly straightforward draft guidance from the FDA for Restasis generics (dry eye)," analyst... More
Allergan (AGN) Slips Lower on FDA Generic Restasis Discussion
June 21, 2013 1:26 PM EDTAllergan (NYSE: AGN) is lower on Friday's session following a new FDA document which discusses generic cyclosporine ophthalmic emulsion (generic Restasis).
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.... More
Goldman Sachs Downgrades Allergen (AGN) to Neutral
June 21, 2013 7:36 AM EDTGoldman Sachs downgraded Allergen (NYSE: AGN) from Buy to Neutral with a price target of $110, saying they see greater upside in Forest Laboratories (NYSE: FRX), which was... More
